Skip to main content

Table 2 Univariate Logistic regression analysis for risk factors with post-thrombolysis END and post-thrombolysis ENI

From: The association of neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, and lymphocyte to monocyte ratio with post-thrombolysis early neurological outcomes in patients with acute ischemic stroke

Variable

Crude model for post-thrombolysis END

Crude model for post-thrombolysis ENI

OR (95%CI)

P

OR (95%CI)

P

Demographic characteristics

 Age

1.033 (1.018–1.048)

0.001

0.982 (0.972–0.993)

0.002

 Male

0.813 (0.587–1.125)

0.211

0.950 (0.729–1.237)

0.702

 BMI

1.032 (0.987–1.079)

0.169

0.974 (0.940–1.010)

0.159

Vascular risk factors

 Hypertension

1.033 (0.737–1.447)

0.851

1.070 (0.819–1.399)

0.629

 Diabetes mellitus

1.254 (0.877–1.794)

0.215

0.711 (0.524–0.964)

0.028

 Dyslipidemia

0.972 (0.682–1.383)

0.873

1.153 (0.872–1.523)

0.317

 Atrial fibrillation

1.385 (0.962–1.995)

0.080

0.828 (0.606–1.130)

0.235

 Current smoking

0.933 (0.665–1.308)

0.687

1.047 (0.802–1.366)

0.737

 Current drinking

1.204 (0.868–1.671)

0.226

1.004 (0.770–1.309)

0.977

 Previous stroke

0.847 (0.574–1.249)

0.402

0.848 (0.625–1.150)

0.288

 Peripheral artery disease

0.813 (0.419–1.577)

0.540

1.235 (0.758–2.012)

0.397

 Coronary artery disease

1.049 (0.708–1.555)

0.810

1.140 (0.833–1.561)

0.412

Medication use history

 Previous antiplatelet

0.469 (0.290–0.760)

0.002

1.504 (1.102–2.053)

0.010

 Previous anticoagulation

1.415 (0.512–3.909)

0.504

0.514 (0.187–1.413)

0.197

 Previous statin

0.848 (0.638–1.127)

0.256

1.050 (0.855–1.289)

0.642

Clinical assessment

 NIHSS

1.051 (1.030–1.072)

0.001

1.007 (0.990–1.024)

0.446

 SBP

0.995 (0.989–1.002)

0.195

0.998 (0.993–1.002)

0.359

 DBP

0.998 (0.993–1.009)

0.737

0.990 (0.982–0.999)

0.023

 HT

3.248 (2.020–5.221)

0.001

0.290 (0.158–0.532)

0.001

 OTT

1.004 (1.001–1.006)

0.011

0.993 (0.990–0.995)

0.001

 PAO

1.894 (1.368–2.623)

0.001

0.634 (0.476–0.843)

0.002

 Endovascular treatment

1.464 (0.997–2.148)

0.052

0.882 (0.633–1.228)

0.456

Stroke subtype

 LAA

Reference

 

Reference

 

 CE

1.065 (0.731–1.552)

0.743

1.194 (0.881–1.618)

0.252

 SAO

0.529 (0.329–0.849)

0.008

0.828 (0.592–1.157)

0.268

 SOE

1.443 (0.623–3.341)

0.392

0.549 (0.240–1.253)

0.154

 SUE

1.844 (1.063–3.197)

0.029

0.941 (0.566–1.563)

0.813

Lesion location

 Anterior circulation

Reference

 

Reference

 

 Posterior circulation

0.890 (0.615–1.288)

0.537

1.147 (0.861–1.528)

0.347

Laboratory data

 TC

1.003 (0.996–1.010)

0.447

0.999 (0.994–1.003)

0.591

 TG

1.000 (0.998–1.002)

0.623

1.001 (0.996–1.005)

0.655

 HDL

1.255 (0.953–1.654)

0.106

0.889 (0.664–1.190)

0.428

 LDL

0.999 (0.992–1.005)

0.708

1.002 (0.998–1.005)

0.415

 FBG

1.084 (1.032–1.138)

0.002

1.035 (0.991–1.080)

0.119

 Hs-CRP

1.033 (1.018–1.048)

0.001

0.997 (0.984–1.010)

0.630

 NLR

1.661 (1.528–1.807)

0.001

0.678 (0.626–0.735)

0.001

 PLR

1.014 (1.011–1.017)

0.001

0.997 (0.995–0.999)

0.004

 LMR

0.869 (0.758–0.996)

0.043

1.152 (1.033–1.284)

0.011

  1. Abbreviation: END early neurological deterioration, ENI early neurological improvement, OR odds ratio, CI confidence interval, BMI body mass index, NIHSS National Institute of Health Stroke Scale, SBP systolic blood pressure, DBP diastolic blood pressure, HT hemorrhagic transformation, OTT onset to treatment time, PAO proximal arterial occlusion, LAA large-artery atherosclerosis, CE cardioembolism, SAO small-artery occlusion, SOE stroke of other determined etiology, SUE, stroke of undetermined etiology, TC total cholesterol, TG triglyceride, LDL low-density lipoprotein, HDL high-density lipoprotein, FBG fasting blood glucose, Hs-CRP hyper-sensitive C-reactive protein, NLR neutrophil-lymphocyte ratio, PLR platelet-lymphocyte ratio, LMR lymphocyte-monocyte ratio
Back to article page

Journal of Neuroinflammation

ISSN: 1742-2094